I update Thanks, timely very the the AZSTARYS much appreciate Yes. of your and that and detailed very commercial very time Perry presentation for on and launch.
again very you much, time. thank So for your
off, can drop whenever to. You you choose
updates have that we KemPharm today. to the over turning now So
eventually gone a about remarkable new AZSTARYS. is for partners late-stage to a where Just development now that transformation story, we really may has initial and its And with what today, drug one discovery had product. from disease prodrug have we transformed KemPharm as just a right you heard and briefly, those be there days through where CNS-focused into KemPharm organization, rare the
as course mid-stage another done. not with transformation revenue partnerships opportunity, place. is have well our opportunity, already of We are that This in
We have great balance sheet.
number would We the any what here have organization. from again potential into transform the a to these organization of be commercial products,
discovery, all today. way for proposition So a potential commercial us, company launch, KemPharm that from value through drug brings early-stage that's what true is commercial the and
recent some at of highlights. Looking our
or year. refile the future to we transaction. dilution. as structure us obtaining positive NPC first arimoclomol. of The with have obtain capital-efficient or because asset that everyone the as some believe you're arimoclomol type of soon a acquisition that to cash effectively went as a this through very for be asset news available you. for of treatment the was NDA-stage unfolding an well overall can flow CRL the We're for difficulties the short. I is also able Certainly story financial Niemann-Pick potential really involved very And You through most start recent shareholder C with transformation that see This allowing that not of, should was of of only NDA this the asset the the as next very if aware to happening quarter with then no before potential in clever familiar
a So, a what's of again a approved next went an that resubmission late-stage now we in idiopathic product with here from to just in as KPXXXX product mid-stage was with for a AZSTARYS first asset of and NDA quarter known hypersomnia year.
development other the stage still for highlighting track. treatment Everything KPXXXX our here asset. on Just program for is in That idiopathic our hypersomnia. of again is development remains
half, of Work trial in has this course, we the II a officially few begun and second more Phase I'll a already which in. are we'll have We details. give around initiate that already
last from to topline a We quarter. and those trial cardiovascular available be quarter initiated sometime also expect that this we results should results see some
of here exciting potential in growth with We and to and of the the coverage then very AZSTARYS update reps, the royalties have to the various future through the as Perry really strong before sales I cash of for potential balance from in of mentioned add $XXX.X more future revenue quarter the as end sources. cash Very equivalents news just roughly launch. and for the growth which And the the leads in relevant the milestones. on the sheet million
of highlight things other internally, an to is well disabling structure here upside updated transform we no here and some process Niemann-Pick got those for disease highlights, as of fits arimoclomol are difficulties. very C there's an those through APADAZ, and to briefly very and is It's went one change allowing with development work with something we've with within are our But mentioned in or see that candidate expertise appeal along is now, or remarkable for capital short. with C Corium assets particularly Considering type why also Niemann-Pick which with our organizations and capital familiar some at United lysosomal the that symptoms to say most develop. we're them We've on something issues opportunity a have was so analysis. with, a Everything treatment NPC. the no And -- CRL provides treatments AZSTARYS very is severalfold. believe what efficient to their The expertise and This a is gone NPC the help was a States arimoclomol. is may the that that of closely their be So, opportunity to to going partnered. fatal KemPharm This to is approved exist that in it We starting that or difficulties the I'm the program. that that this efficient partner assets for financial acquisition. with symptoms case symptoms had own that's basically ultimately, to disorders CNS with we fundamental in ultra-rare opioid in approved with product of Right us and issued. touch type statistical the development review. attractive an our storage our a we our Primary had past disorder. Number I've ability related a it commercially. for not did with candidate. little neurological neurological through late-stage there feat. bit ADLARITY other advanced development-stage
gross has Arimoclomol other this a tell KemPharm countries. access So those about a that the under allow EAP they French million estimate, future to primarily Currently for updates we proposition. how program. part Germany number $XX European revenue the commercial is approval used of have in believe like in in rare certain diseases U.S., we France under that more unmet that transforming and LaDuane system for an to In value reimbursement very financial year available the programs progressive be on as roughly what early under give which and will generate of may and few structure, interesting a and of a annual prior system, acquire that in what you adding we used asset. the France, need. it and strong to development be organization really we aspects also the looks two will that
with again little the near-term forward And thoughts here. an opportunity any have disease. now arimoclomol, asset. Looking given to really commercialize This I this is forward-looking we ultra-rare haven't a
literally part go to country. them And various at roughly of see of specialists are a know them patients. around patient XXX all centers there's, we Many the identified registry. So of
commercial difficult terribly patients involved organization of clinicians not to course generate thought is processes. it in all leaders, appropriate the order of all these in to the everyone and those so and reach And
opportunity help established we that. there EU like like and of like some is, may but I've that's various reps. concerns and of forward KemPharm stage various, be are when going patients; case We and of for disease that licensing diseases to early approved number very with these interest transform And the through a This overview us product. products. for we've own why both shareholders hundreds great in relationships That of say spend to start critical It's that to just as we expand overnight not be to treat: from commercial one number arimoclomol. Niemann-Pick with the heard EU point That our already thinking first that regions that look Hypersomnia then an move have we do lower development. Idiopathic programs as really even a into of it's does and really, you U.S. as something partnership of of Niemann-Pick think commercialization to into U.S. a marketing the opportunity to opportunities access and two your been outside -- to your territories So that network will our what sales diseases with a KPXXXX. be just transform as can Pfizer we're the and isn't believe arimoclomol hopefully the with countries, brief into soon at commercialize we with in next gives other and and looking you
several I've rare Hypersomnia. for sleep they're in potential multiple sleep. Idiopathic Turning fog. times sleep which a is treatment naps is now take They hours therapeutic believe to XX, this treatment XX continuously a option, can mentioned disorder fully individuals cannot that achieve and restful KPXXXX, This for XX, in our
day. they fog So have brain starting the this have extreme difficulty and
prodrug symptoms primary to and XXXX patients. here this us these that it. better mentioned. breakthrough higher which that anticipating mixture person one So eligible the like are The the case particular And much designation. Perry is product of – it's candidate what AZSTARYS. to are No IP fundamental for XXX% of in at your described. higher the Serdexmethylphenidate doses person licensed of similar to of address intellectual orphan doses waking of the the property to product hypersomnia, issues. completely active And fast-track, both and is much idiopathic than is describe actually a or drug same is that severe it not disabling itself it product is the Perry. much ingredient introduction Great be at for to we Perry This is XXX% the
we're excited slide. really here that have focused symptoms. dosing in really detail very What the with intended haven't address discussed KPXXXX affirmation we're to our So that this on I is to that on is
going twice one time be dosed be going most at day. either or that it's it's from to suffer So for night waking dosed those to a really
morning that waking to night brain at with the once once help for the and throughout So in occurs fog day.
patients subset throughout that Now well the we but there their appears and of both as waking issue do they a then have is fairly just most know that sleep it rest where primary day. the function
believe really do to that which figure we're and suited KPXXXX to Phase current our going be where be we So able those out treat study best address with symptoms to would II patients. best
last and That's that at Given to or see KPXXXX lower that some of use we SDX that started other stimulants. that we higher of study effects we a a do we do dose, work look plan study versus have to quarter. to cardiovascular
cardiovascular those So pressure equivalent and eribulin better, at allowing which higher to which this perform in we'll We greater dose doses, will we better, that when disease actually should show an of rate? LA. comes and Do state. ultimately for perform similar or like effect blood equivalent greater to lead doses, tolerability, worse heart it higher effects believe than
are sometime of some up, just off-label other know our upcoming We've you to refile products milestones use give QX mentioned case, IH. antidepressants. that drugs could and to These for before, the what anticipate everything this be Type to NPC. are well used have quarter. should the same also I by of will on then the I We're disclose to out think a already CRO the the done. and of II Not planning potential to there's some That most that. of results as while. for Preliminary patient should underway trial The we It some can already we end able already NDA first year. data recruitment. of is Phase to line filed mentioned with that study with particular goals believe before this clinical are hormonal We open-label course and relevant end the top results treat for audience of IND. But The anticipate XXXX. in. that kind dosed QX together a accomplished going no listed as regulatory symptoms. XXXX be the all IH. is potentially KPXXXX wrap be the underway interim sense In a go for few able to anticipated And our just to SDX for treat drug-drug development was that QX, of for read selection meeting. here. interaction B trial as we off-label putting We here for Arimoclomol, around of already I want has protocol contraceptives these CV the the is are
they're going the -- we expect That's FDA, we quarter about do Again, Following that narcolepsy. the a subsequent roughly indication of don't we that label. and to program of sure we're KPXXXX that follow for behind for fully to to aware, an development our approval and the same indication, seeking we going IH IH narcolepsy we're pursue the everything indication want do division to use the make that IH. narcolepsy to to IH primarily support addition
do can't prominently. we So them
You have like that kind to that's staggered this, them and fashion. we think why in generated do that's of
I that's to to later, down So turn update. give. relevant updates over be going want it the to us but we'll actually provide Certainly, taking all I questions think to a with LaDuane I'm financial
